Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. Br J Haematol. 2014 Nov; 167(3):337-45.